Gastric‐Type Adenocarcinoma of the Uterine Cervix From 2013 to 2023: Clinical Characteristics and Outcomes

AIM: To summarize our experience with gastric-type adenocarcinoma of the uterine cervix (GAS) at multiple cancer centres. METHODS: This retrospective study included patients diagnosed with GAS (from 1 June 2013 to 1 July 2023) from three collaborating institutions. Kaplan-Meier survival analysis was used to determine progression-free survival (PFS) and overall survival (OS). RESULTS: Among the 116 patients with GAS, 71 had negative human papillomavirus (HPV) genotyping results: ThinPrep cytologic test negative for intraepithelial lesion or malignancy in 45; atypical squamous cells of undetermined significance in 8; atypical squamous cells, which cannot exclude a high-grade squamous intraepithelial lesion, in 2; low-grade squamous intraepithelial lesion in 2; high-grade squamous intraepithelial lesion in 5; atypical glandular cell in 19; and adenocarcinoma in 3 patients. Most patients with GAS had advanced stage disease, with only 32.8% having stage I disease. The International Federation of Gynecology and Obstetrics stages were IB, II, III, and IV in 38, 11, 40, and 18 patients, respectively. The median PFS times for stage I and II-IV diseases were 74.9 and 61.3 months, respectively. The median OS times for patients with stage I and II-IV GAS were 109.7 and 87.6 months, respectively. The median PFS times were 74.9, 75.7, 60.3, and 12.8 months for stages I, II, III, and IV, respectively. CONCLUSIONS: GAS is an aggressive form of cervical cancer with poor OS when diagnosed at stage II or higher.